| Title | Tenofovir disoproxil fumarate: in chronic hepatitis B. | | Author(s) | Perry CM, Simpson D | | Institution | Adis, a Wolters Kluwer Business, Auckland, New Zealand. | | Source | Drugs 2009; 69(16):2245-56. | | Abstract | black triangle Tenofovir disoproxil fumarate (tenofovir DF) is an orally administered ester prodrug of tenofovir, a nucleotide reverse transcriptase inhibitor that shows potent in vitro activity against both hepatitis B virus (HBV) and HIV-1. black triangle As a component of antiretroviral combination therapy regimens, tenofovir DF is well established in the treatment of adults with HIV-1 infection. Tenofovir DF, administered once daily, is also used in the treatment of adults with chronic hepatitis B (CHB) [the main focus of this profile]. black triangle In CHB, the efficacy of tenofovir DF against HBV has been evaluated in two large randomized, phase III clinical studies in hepatitis B e antigen (HBeAg)-negative or HBeAg-positive adults, with compensated liver function. The trials (planned duration 8 years) were double-blind for the first 48 weeks; thereafter, patients received open-label tenofovir DF. Results at 48 and 96 weeks are available. black triangle In these studies, at week 48, a significantly greater proportion of recipients of tenofovir DF 300 mg once daily than oral adefovir dipivoxil 10 mg once daily achieved a complete response (primary endpoint). A complete response was defined as a reduction from baseline in plasma HBV DNA level to <400 copies/mL and histological improvement (reduction of 2 or more points in Knodell necroinflammatory score without worsening of fibrosis). black triangle The efficacy of tenofovir DF in the treatment of CHB was also demonstrated over a 96-week treatment period in both studies. black triangle Tenofovir DF was generally well tolerated by adults with CHB in the two phase III trials. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19852527 |
|
